Acquire the license to the best health content in the world
Contact Us

Protease Mutation in HIV-1 Linked with Drug Resistance

Mutation M891/V more common in patients with therapy failure

MONDAY, Nov. 7 (HealthDay News) -- Patients with protease inhibitor-resistant HIV infections are more likely to have viruses with the protease mutation M891/V, according to a study in the Nov. 4 issue of AIDS. However, this is true for patients with HIV-1 subtypes C, F and G, but not subtype B.

Ana Barroso Abecasis, of the Rega Institute for Medical Research, Katholieke Universiteit Leuven in Belgium, and colleagues investigated the relationship between mutations at codon 89 of HIV-1 protease and protease inhibitor failure, and the impact of the HIV-1 subtype.

They found that patients with drug-resistant HIV were more likely to have the M891/V than drug-naive patients if infected with subtypes C, F and G.

"M891/V should be considered a secondary protease inhibitor mutation with an important effect on nelfinavir susceptibility in the presence of L90M," they conclude.

Full Text (payment may be required)

Physician's Briefing